<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>11(3)</volume><submitter>Devarbhavi H</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Etiology of and outcomes following idiosyncratic drug-induced liver injury (DILI) vary geographically. We conducted a prospective study of DILI in India, from 2013 to 2018 and summarize the causes, clinical features, outcomes and predictors of mortality.&lt;h4>Methods&lt;/h4>We enrolled patients with DILI using international DILI expert working group criteria and Roussel Uclaf causality assessment method. Follow-up was up to 3 months from onset of DILI or until death. Multivariate logistics regression was carried out to determine predictors of non-survival.&lt;h4>Results&lt;/h4>Among 1288 patients with idiosyncratic DILI, 51.4% were male, 68% developed jaundice, 68% required hospitalization and 8.2% had co-existing HIV infection. Concomitant features of skin reaction, ascites, and encephalopathy (HE) were seen in 19.5%, 16.4%, and 10% respectively. 32.4% had severe disease. Mean MELD score at presentation was 18.8 ± 8.8. Overall mortality was 12.3%; 65% in those with HE, 17.6% in patients who fulfilled Hy's law, and 16.6% in those that developed jaundice. Combination anti-TB drugs (ATD) 46.4%, complementary and alternative medicines (CAM) 13.9%, anti-epileptic drugs (AED) 8.1%, non-ATD antimicrobials 6.5%, anti-metabolites 3.8%, anti-retroviral drugs (ART)3.5%, NSAID2.6%, hormones 2.5%, and statins 1.4% were the top 9 causes. Univariate analysis identified, ascites, HE, serum albumin, bilirubin, creatinine, INR, MELD score (p &lt; 0.001), transaminases (p &lt; 0.04), and anti-TB drugs (p = 0.02) as predictors of non-survival. Only serum creatinine (p = 0.017), INR (p &lt; 0.001), HE (p &lt; 0.001), and ascites (p = 0.008), were significantly associated with mortality on multivariate analysis. ROC yielded a C-statistic of 0.811 for MELD and 0.892 for combination of serum creatinine, INR, ascites and HE. More than 50 different agents were associated with DILI. Mortality varied by drug class: 15% with ATD, 13.6% with CAM, 15.5% with AED, 5.8% with antibiotics.&lt;h4>Conclusion&lt;/h4>In India, ATD, CAM, AED, anti-metabolites and ART account for the majority of cases of DILI. The 3-month mortality was approximately 12%. Hy's law, presence of jaundice or MELD were predictors of mortality.</pubmed_abstract><journal>Journal of clinical and experimental hepatology</journal><pagination>288-298</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8103312</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The Indian Network of Drug-Induced Liver Injury: Etiology, Clinical Features, Outcome and Prognostic Markers in 1288 Patients.</pubmed_title><pmcid>PMC8103312</pmcid><pubmed_authors>Arora A</pubmed_authors><pubmed_authors>Krishna Dhali G</pubmed_authors><pubmed_authors>Adarsh CK</pubmed_authors><pubmed_authors>Rao P</pubmed_authors><pubmed_authors>Koshy A</pubmed_authors><pubmed_authors>Nagral A</pubmed_authors><pubmed_authors>Shalimar</pubmed_authors><pubmed_authors>Joseph T</pubmed_authors><pubmed_authors>Kumar Jain A</pubmed_authors><pubmed_authors>Eapen CE</pubmed_authors><pubmed_authors>Leelakrishnan V</pubmed_authors><pubmed_authors>Duseja AK</pubmed_authors><pubmed_authors>Dhiman R</pubmed_authors><pubmed_authors>Jhaveri A</pubmed_authors><pubmed_authors>Patel R</pubmed_authors><pubmed_authors>Goswami B</pubmed_authors><pubmed_authors>Thomas V</pubmed_authors><pubmed_authors>Nijhawan S</pubmed_authors><pubmed_authors>Kumar Sarin S</pubmed_authors><pubmed_authors>Prasad Singh S</pubmed_authors><pubmed_authors>Rai P</pubmed_authors><pubmed_authors>Vardhan Reddy V</pubmed_authors><pubmed_authors>Singh R</pubmed_authors><pubmed_authors>Balaraju G</pubmed_authors><pubmed_authors>Ganesh P</pubmed_authors><pubmed_authors>Gopalakrishnan G</pubmed_authors><pubmed_authors>Patil M</pubmed_authors><pubmed_authors>Wadhawan M</pubmed_authors><pubmed_authors>Nagaraja Rao P</pubmed_authors><pubmed_authors>Goel A</pubmed_authors><pubmed_authors>Sunil Kumar N</pubmed_authors><pubmed_authors>Rathi P</pubmed_authors><pubmed_authors>Karanth D</pubmed_authors><pubmed_authors>Devarbhavi H</pubmed_authors><pubmed_authors>Rathi C</pubmed_authors><pubmed_authors>Venkataraman J</pubmed_authors><pubmed_authors>Sawant P</pubmed_authors><pubmed_authors>Taneja S</pubmed_authors><pubmed_authors>Vargese J</pubmed_authors><pubmed_authors>Ranjan P</pubmed_authors></additional><is_claimable>false</is_claimable><name>The Indian Network of Drug-Induced Liver Injury: Etiology, Clinical Features, Outcome and Prognostic Markers in 1288 Patients.</name><description>&lt;h4>Background&lt;/h4>Etiology of and outcomes following idiosyncratic drug-induced liver injury (DILI) vary geographically. We conducted a prospective study of DILI in India, from 2013 to 2018 and summarize the causes, clinical features, outcomes and predictors of mortality.&lt;h4>Methods&lt;/h4>We enrolled patients with DILI using international DILI expert working group criteria and Roussel Uclaf causality assessment method. Follow-up was up to 3 months from onset of DILI or until death. Multivariate logistics regression was carried out to determine predictors of non-survival.&lt;h4>Results&lt;/h4>Among 1288 patients with idiosyncratic DILI, 51.4% were male, 68% developed jaundice, 68% required hospitalization and 8.2% had co-existing HIV infection. Concomitant features of skin reaction, ascites, and encephalopathy (HE) were seen in 19.5%, 16.4%, and 10% respectively. 32.4% had severe disease. Mean MELD score at presentation was 18.8 ± 8.8. Overall mortality was 12.3%; 65% in those with HE, 17.6% in patients who fulfilled Hy's law, and 16.6% in those that developed jaundice. Combination anti-TB drugs (ATD) 46.4%, complementary and alternative medicines (CAM) 13.9%, anti-epileptic drugs (AED) 8.1%, non-ATD antimicrobials 6.5%, anti-metabolites 3.8%, anti-retroviral drugs (ART)3.5%, NSAID2.6%, hormones 2.5%, and statins 1.4% were the top 9 causes. Univariate analysis identified, ascites, HE, serum albumin, bilirubin, creatinine, INR, MELD score (p &lt; 0.001), transaminases (p &lt; 0.04), and anti-TB drugs (p = 0.02) as predictors of non-survival. Only serum creatinine (p = 0.017), INR (p &lt; 0.001), HE (p &lt; 0.001), and ascites (p = 0.008), were significantly associated with mortality on multivariate analysis. ROC yielded a C-statistic of 0.811 for MELD and 0.892 for combination of serum creatinine, INR, ascites and HE. More than 50 different agents were associated with DILI. Mortality varied by drug class: 15% with ATD, 13.6% with CAM, 15.5% with AED, 5.8% with antibiotics.&lt;h4>Conclusion&lt;/h4>In India, ATD, CAM, AED, anti-metabolites and ART account for the majority of cases of DILI. The 3-month mortality was approximately 12%. Hy's law, presence of jaundice or MELD were predictors of mortality.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 May-Jun</publication><modification>2025-04-04T10:17:14.656Z</modification><creation>2025-04-04T10:17:14.656Z</creation></dates><accession>S-EPMC8103312</accession><cross_references><pubmed>33994711</pubmed><doi>10.1016/j.jceh.2020.11.002</doi></cross_references></HashMap>